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Based on the goal of delivering innovative and reliable pharmaceutical products to cancer
patients for whom no effective treatments exist, Astellas is focusing its efforts on a strategy of
precision medicine in its drug discovery which is carried out at three research sites with diver-
sity in their research platforms and research styles.
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INTRODUCTION
Astellas Pharma Inc. was formed in April 2005 by the
merger of two research and development (R&D)-driven
companies, namely Yamanouchi Pharmaceutical Co., Ltd,
and Fujisawa Pharmaceutical Co., Ltd. ‘Astellas’ expresses
the idea of ‘aspired stars’ and ‘advanced stars’ based on the
Latin ‘stella’, Greek ‘aster’ and English ‘stellar’, which all
refer to ‘stars’. ‘Astellas’ also sounds like the Japanese
phrase ‘a-su wo te-ra-su’ which means ‘to shine on tomor-
row’ (1).
In this paper, we describe our drug discovery strategy
in view of our guiding principles, current research
activities and future perspectives, with a particular focus on
oncology.
OUR GUIDING PRINCIPLES: PHILOSOPHY,
MESSAGE AND VISION
At our very start, we clariﬁed our guiding principles as our
philosophy, corporate message and vision. Our philosophy is
to contribute toward improving the health of people around
the world through the provision of innovative and reliable
pharmaceutical products. Our corporate message is that we
will be the ‘Leading Light for Life’ to deliver world-class
state-of-the-art pharmaceuticals that promise people from
around the world a healthier life (2). For patients and their
families and for ourselves, we have further condensed our
message into the phrase ‘Changing tomorrow’ (3).
We went on to decide ‘VISION 2015’ as our management
vision in order to show how Astellas must look in the
year 2015. In this vision, we constructed our business
model, a ‘Global Category Leader’ (GCL). A GCL shows
high competitiveness by providing value-added products
globally in several categories where high unmet medical
needs exist and a high degree of expertise is required,
and thereby takes a leading position in such ‘categories’.
At the same time, we established our important R&D
categories including urology, immunology including
transplantation and infectious diseases, neuroscience,
diabetes mellitus complications and metabolic diseases, and
oncology (4).
OUR RESEARCH PLATFORM
We strongly believe that we need to reinforce our research
capabilities by approaching new technologies and new re-
search areas in a timely manner in order to create innovative
drugs (5). In 2009, we started operation of an X-ray beam
line at the Photon Factory of the High Energy Accelerator
Research Organization, Tsukuba, purposely built for efﬁcient
elucidation of protein structures for use by Astellas and aca-
demic institutions (6)( F i g .1). We also created the
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doi:10.1093/jjco/hys014Figure 1. Astellas beamline at the High Energy Accelerator Research Organization (KEK). Left: Aerial view of the KEK campus located 9 km north of the
Astellas Tsukuba Research Center. Top right: The plan of the PF-AR experimental hall. Astellas beam line (red color) is placed in the NE3 section. Bottom
right: The NE-3A deck for X-ray diffraction experiments colored in Red and Gray (Astellas Corporate Brand Color). AR-NE3A, an X-ray beamline with a
beam energy of 6.5 GeV ring, is designed for high-throughput macromolecular crystallography which is applied in a structure-based drug design (SBDD).
KEK and Astellas jointly developed a fully automated data collection and processing system inside the NE-3A deck. This system can collect X-ray diffraction
data sets from more than 200 samples per day by optimizing the schedules of sample exchange, centering, data collection and data processing.
Figure 2. Astellas’ Bioimaging Research Laboratories (BIRL). Upper left: Building of BIRL at Astellas Tsukuba Research Center. Upper right: Automated
system for PET tracers developed in-house. Lower left: Positron emission tomography (PET)/computed tomography scanner for small animal studies (Inveon,
Siemens). Lower right: PET scanner for large animal studies (SHR-17000, co-developed with Hamamatsu Photonics K.K.).
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Center in order to enhance our capability in drug discovery
and translational sciences (7)( F i g .2). In addition, we are
keen to strengthen our capability in other important technol-
ogy platforms including proteomics (8) and bioinformatics
(9,10).
In view of treatment modality, Astellas had specialized
primarily in small molecules, including natural products.
Therefore, we in-licensed VelocImmune technology from
Regeneron Pharmaceuticals, Inc., in order to efﬁciently gen-
erate fully human monoclonal antibodies (11) and acquired
Agensys, Inc., in order to strengthen our drug discovery of
antibodies in cancer (12).
OUR RESEARCH APPROACH
Based on our in-house research and introduction from other
companies in the past few years, our current oncology R&D
programs consist of the following three approaches (13):
(i) Precision medicine
(ii) Mechanisms of action with application across mul-
tiple tumor types
(iii) Leveraging Astellas’ current capabilities in urology
and other therapeutic area
In the past, we took the second and third approaches in
our drug discovery. From the second approach, we created
YM155, a selective survivin suppressant for multiple tumors
(14,15). From the third approach, we created potential treat-
ments for hormone-dependent cancers including YM511, an
aromatase inhibitor (16), and YM580, a non-steroidal andro-
gen receptor antagonist (17). Through our experience in
these drug discovery programs and subsequent clinical trials,
we had fostered the notion that we must deliver novel therap-
ies for improving the health of well-deﬁned populations of
patients suffering from a number of cancers.
The establishment of our principles on top of the above-
mentioned mindset naturally shifted our research approach in
a direction in which we can offer highly effective therapeutic
options for precisely deﬁned patient populations based on
molecular targeting and precise diagnosis. We call it the pre-
cision medicine approach (5,13,18) (Fig. 3).
Precision medicine is becoming a treatment option for
certain cancers. In July 2011, the US Food and Drug
Administration (FDA) published the draft guidance for in
vitro companion diagnostic devices (19). In August 2011,
the FDA approved ZelborafTM (vemurafenib), a kinase in-
hibitor, for the treatment of patients with unresectable or
metastatic melanoma whose tumors express a gene mutation
called BRAF V600E together with a diagnostic test to detect
such mutation in patients’ melanoma cells (20). The FDA
also approved Xalkori
w (crizotinib), a kinase inhibitor, for
the treatment of patients with locally advanced or metastatic
non-small cell lung cancer who express the abnormal ana-
plastic lymphoma kinase (ALK) gene together with a diag-
nostic test to detect such abnormal gene (21)
ACTIVITIES IN OUR RESEARCH SITES
Astellas has three sites for oncology drug discovery, namely
Astellas Pharma Inc. Tsukuba Research Center at Tsukuba,
Ibaraki, Japan, OSI Pharmaceuticals, LLC at Farmingdale,
NY, USA, and Agensys, Inc. at Santa Monica, CA, USA.
The three research sites pursue precision medicine in a
diverse manner based on the research platform and research
strategy of each site.
Tsukuba Research Center focuses on the creation of small
molecules that inhibit the function of molecules which are
essential for the survival or growth of tumor cells as a result
of either genetic or epigenetic alterations to the drug target
molecules themselves or in the presence of certain genetic or
epigenetic contexts. In order to create drugs to well-deﬁned
patient populations, Tsukuba Research Center is placing sig-
niﬁcant emphasis on efforts to identify and validate novel
molecular targets based on in-house research and external
collaborations. It should be noted that these ‘target discov-
ery’ efforts also form the basis of translational research for
determination of the right patients. Based on this research
style, we created ASP3026, an inhibitor of ALK tyrosine
kinase (22,23).
OSI joined Astellas in 2010 (24), and it is pursuing small
molecule drug discovery with a different style using different
precision medicine strategies. During the development of
erlotinib, an inhibitor of epidermal growth factor receptor
tyrosine kinase, OSI completed much research to better
understand which patients optimally beneﬁt from this
therapy and which patients would become refractory or re-
sistant (25–27). This research led OSI to focus on drug dis-
covery and translational research related to epithelial–
mesenchymal transition (26,28,29) and compensatory activa-
tion mechanisms in oncogenic signal transduction (27,30,31)
for both publicly known as well as novel oncology targets.
In addition, OSI is doing extensive translational research to
identity novel biomarkers for patient selection based on the
characterization of gene and protein signatures in responsive
tumor cells (32).
Agensys joined Astellas in 2007 (12). Agensys specializes
in drug discovery of antibodies for cancer therapy, focusing
on the creation of novel monoclonal antibodies from two
Figure 3. Astellas’ precision medicine approach. Astellas would like to
realize ‘right drug for right patients’ by offering medicines targeting patho-
genic molecules (we call it Precision Medicine) combined with companion
diagnostic tests ﬁtting to such medicines.
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molecules or epitopes which are selectively expressed on the
surface of certain sets of tumor cells. These antigen mole-
cules or epitopes are molecular targets for Agensys’ anti-
bodies as well as biomarkers for the selection of the right
patients. Agensys is focusing to create antibody–drug conju-
gates (ADCs, also known as ‘immunoconjugates’) to these
antigens. ADC is an antibody covalently attached to a cyto-
toxic molecule (such as tubulin inhibitor or DNA minor
groove binder) via a linker. Once an ADC binds to the
antigen on a tumor cell, it is internalized into the tumor cell
and the cytotoxic molecule is released to cause cell death
(33). This unique combination of novel molecular targets
and ADC technology is expected to provide innovative thera-
peutic options for precision medicine to the patients for
whom no effective drug currently exists. Agensys has put
three ADCs into clinical trials so far, with AGS-22M6E
(also known as ASG-22ME), an ADC targeting nectin-4, as
the latest example (34). Secondly, Agensys is using its panel
of patient-derived xenografts (PDX) to validate antibody
targets in cancers and develop functional antibodies. The
panel of over 60 PDX, representing 14 different indications,
provides unique preclinical models and allows preclinical
evaluation of targets that are required for tumor growth and
survival in a particular microenvironment that may not be
found or required for growth of xenografts of conventional
cell lines. The anti-prostate stem cell antigen antibody
AGS-1C4D4 completing a Phase II study in pancreatic
cancer is the most advanced example of this approach
(35,36).
The chemical compounds and antibodies created by our
three research sites, together with in-licensed compounds,
form our oncology development pipeline as shown in
Table 1.
Table 1. Astellas’ oncology development pipeline
Code no., generic name Classiﬁcation Therapeutic target Phase Origin Remarks
ASP3550, degarelix GnRH receptor
antagonist
Prostate cancer Filed Ferring
Pharmaceuticals
MDV3100 Androgen antagonist Prostate cancer III Medivation
Erlotinib (Tarceva) HER1/EGFR
tyrosine kinase
inhibitor
Non-small cell lung cancer (ﬁrst line for
patients with EGFR mutation, adjuvant),
hepatocellular carcinoma
III In-house (OSI) New indication
OSI-906 IGF-1R/IR tyrosine
kinase inhibitor
Adrenocortical carcinoma (ACC),
ovarian cancer, non-small cell lung
cancer, hepatocellular carcinoma
III (ACC),
II (others)
In-house (OSI) Ref. (30)
ASP4130, tivozanib Triple VEGF
receptors inhibitor
Renal cell carcinoma (RCC), breast
cancer, colorectal cancer
III (RCC),
II (others)
AVEO
Pharmaceuticals, Inc.
YM155 Survivin suppressant Breast cancer, non-Hodgkin’s lymphoma II In-house (Tsukuba) Refs (14,15)
AC220 FLT3 kinase
inhibitor
Acute myeloid leukemia II Ambit Biosciences
Corporation
AGS-1C4D4 Antibody (prostate
stem cell antigen)
Pancreatic cancer II In-house (Agensys) Refs (34,35)
OSI-027 mTOR kinase
inhibitor
Renal cell carcinoma II In-house (OSI)
AGS-16M8F Antibody-drug
conjugate (ADC)
Cancer I In-house (Agensys)
ASG-5ME ADC Cancer I In-house (Agensys) Co-development with
Seattle Genetics
ASP1707 Small molecule Prostate cancer, endometriosis I In-house (Tsukuba)
ASP3026 ALK kinase inhibitor Cancer I In-house (Tsukuba) Refs (21,22)
ASP9521 Small molecule Prostate cancer I In-house (Tsukuba)
AGS-22M6E ADC Cancer I In-house (Agensys) Ref. (33),
Co-development with
Seattle Genetics
GnRH, gonadotropin-releasing hormone; HER1, human epidermal growth factor receptor 1; EGFR, epidermal growth factor receptor; IGF-1R, insulin-like
growth factor receptor 1; IR, insulin receptor; VEGF, vascular endothelial growth factor; FLT3, fetal liver tyrosine kinase 3.
This table is based on the status of November 2011. Astellas is not developing YM511 or YM580. Astellas has out-licensed FK228 to Gloucester
Pharmaceuticals Inc. (currently Celgene Corporation) and YM753 to Oncolys BioPharma Inc.
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span sites on the basis of research programs as well as plat-
form technologies. The research activities at the sites are
coordinated through a team consisting of research leaders,
clinical leaders, including medical oncologists, and strategy
leaders. This team reviews the research activities of each site
and offers ideas for improvement of research programs at
each site and to facilitate further collaboration.
In concluding this chapter, we would like to describe how
we tackle rapidly progressing ﬁelds, taking epigenetics as an
example. When molecules involved in epigenetic modiﬁca-
tion of histone emerged as therapeutic targets, both of our
parent companies utilized their natural product technology
platform to the discover histone deacetylase inhibitors,
namely FK228 and YM753 (37). Since then, a number of
epigenetic modiﬁcation mechanisms have been identiﬁed as
potential therapeutic targets and biomarkers (38), and we now
see this progress as an opportunity for novel drug discovery
based on our current mindset and technology platforms.
FUTURE PERSPECTIVES
We have described our research activities with emphasis on
what we are doing in our research sites. However, our re-
search activities are already based on a number of external
collaborations (39), and we seek further opportunity of such
collaborations in order to create and deliver novel treatments
to cancer patients. We understand that such opportunity is
not only in the accomplishments of basic science, but also in
the ﬁndings and insights derived from clinical practice.
While we understand that the feedback of clinical ﬁndings to
drug discovery in a timely and appropriate manner is a big
challenge, it is our hope that we can take this challenge with
the readers of this paper.
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